Anbio Biotechnology Ltd
Anbio Biotechnology Ltd is a medical device company focused on in vitro diagnostics. Anbio Biotechnology develops and supplies diagnostic products for over-the-counter use, point-of-care testing, and laboratory applications, serving healthcare providers and patients in multiple settings. Its portfolio spans several testing technologies, including fluorescence immunoassay, chemiluminescence immunoassay, lateral flow immunoassay, loop-mediated isothermal amplification, dry chemistry, and real-time polymerase chain reaction. The company also offers rapid antigen test kits for respiratory infections and other diagnostic needs. With a global presence across major international markets, Anbio Biotechnology plays a role in expanding access to fast, decentralized diagnostic tools used in infectious disease detection and broader biomarker testing.
$3.79
+$0.06 (+1.61%)
EOD Oct 21, 2026
Margins and capital returns are both well above average: 66.70% operating margin, ROIC at 24.36%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 5.6%, steady but not accelerating. Free cash flow declined 424% despite revenue growth, conversion is weakening.
At 26x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 424% versus the prior year, cash generation momentum has weakened.
26.0x earnings. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$9M
▲ +5.6% YoY
Net Income (TTM)
$6M
▲ +169.9% YoY
Op. Margin
66.70%
▲ +42.3pp YoY
ROIC
24.36%
▲ +11.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$7M
▼ -423.9% YoY
Op. Cash Flow (TTM)
-$7M
▼ -423.9% YoY
Net Debt
-$12M
Net Cash Position
Cash & Equiv.
$12M
3Y CAGR: -28.4%
Continue Research
Is Anbio Biotechnology (NNNN) overvalued?
At a P/E of 26.0, Anbio Biotechnology (NNNN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Anbio Biotechnology scores 51/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Anbio Biotechnology a high-quality business?+
Anbio Biotechnology scores 51 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 66.7% operating margin and a 24.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Anbio Biotechnology a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh NNNN's valuation and scores 51/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Instruments & Supplies
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NNNN
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.